1
|
Guo N, Gao C, Liu J, Li J, Liu N, Hao Y, Chen L, Zhang X. Reversal of Ovarian Cancer Multidrug Resistance by a Combination of LAH4-L1-siMDR1 Nanocomplexes with Chemotherapeutics. Mol Pharm 2018; 15:1853-1861. [PMID: 29621396 DOI: 10.1021/acs.molpharmaceut.8b00031] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Nana Guo
- Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing 100084, China
- Anhui Medical University, Hefei, Anhui 230032, China
- Department of Gynaecology and Obstetrics, PLA Navy General Hospital, Beijing 100037, China
| | - Chen Gao
- College of Life Science, Hebei Normal University, Shijiazhuang, Hebei 050024, China
| | - Jing Liu
- Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing 100084, China
| | - Jun Li
- School of Life Science, Jiangsu Normal University, Xuzhou, Jiangsu 221116, China
| | - Nan Liu
- School of Medicine, Tsinghua University, Beijing 100084, China
| | - Yanli Hao
- School of Medicine, Tsinghua University, Beijing 100084, China
| | - Lei Chen
- Anhui Medical University, Hefei, Anhui 230032, China
- Department of Gynaecology and Obstetrics, PLA Navy General Hospital, Beijing 100037, China
| | - Xiaoning Zhang
- Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing 100084, China
- School of Medicine, Tsinghua University, Beijing 100084, China
| |
Collapse
|
2
|
Schaefer C, Mallela N, Seggewiß J, Lechtape B, Omran H, Dirksen U, Korsching E, Potratz J. Target discovery screens using pooled shRNA libraries and next-generation sequencing: A model workflow and analytical algorithm. PLoS One 2018; 13:e0191570. [PMID: 29385199 PMCID: PMC5792015 DOI: 10.1371/journal.pone.0191570] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2017] [Accepted: 01/08/2018] [Indexed: 11/28/2022] Open
Abstract
In the search for novel therapeutic targets, RNA interference screening has become a valuable tool. High-throughput technologies are now broadly accessible but their assay development from baseline remains resource-intensive and challenging. Focusing on this assay development process, we here describe a target discovery screen using pooled shRNA libraries and next-generation sequencing (NGS) deconvolution in a cell line model of Ewing sarcoma. In a strategy designed for comparative and synthetic lethal studies, we screened for targets specific to the A673 Ewing sarcoma cell line. Methods, results and pitfalls are described for the entire multi-step screening procedure, from lentiviral shRNA delivery to bioinformatics analysis, illustrating a complete model workflow. We demonstrate that successful studies are feasible from the first assay performance and independent of specialized screening units. Furthermore, we show that a resource-saving screen depth of 100-fold average shRNA representation can suffice to generate reproducible target hits despite heterogeneity in the derived datasets. Because statistical analysis methods are debatable for such datasets, we created ProFED, an analysis package designed to facilitate descriptive data analysis and hit calling using an aim-oriented profile filtering approach. In its versatile design, this open-source online tool provides fast and easy analysis of shRNA and other count-based datasets to complement other analytical algorithms.
Collapse
Affiliation(s)
- Christiane Schaefer
- Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany
| | - Nikhil Mallela
- Institute of Bioinformatics, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - Jochen Seggewiß
- Institute of Human Genetics, University Hospital Münster, Münster, Germany
| | - Birgit Lechtape
- Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany
| | - Heymut Omran
- General Pediatrics, University Hospital Münster, Münster, Germany
| | - Uta Dirksen
- Department of Hematology and Oncology, Pediatrics III, West German Cancer Center, German Cancer Consortium (DKTK) Center Essen, University Hospital Essen, Essen, Germany
| | - Eberhard Korsching
- Institute of Bioinformatics, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - Jenny Potratz
- Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany
- General Pediatrics, University Hospital Münster, Münster, Germany
- * E-mail:
| |
Collapse
|
3
|
Kandeel M, Al-Taher A, Nakashima R, Sakaguchi T, Kandeel A, Nagaya Y, Kitamura Y, Kitade Y. Bioenergetics and gene silencing approaches for unraveling nucleotide recognition by the human EIF2C2/Ago2 PAZ domain. PLoS One 2014; 9:e94538. [PMID: 24788663 PMCID: PMC4008379 DOI: 10.1371/journal.pone.0094538] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2013] [Accepted: 03/18/2014] [Indexed: 12/27/2022] Open
Abstract
Gene silencing and RNA interference are major cellular processes that control gene expression via the cleavage of target mRNA. Eukaryotic translation initiation factor 2C2 (EIF2C2, Argonaute protein 2, Ago2) is considered to be the major player of RNAi as it is the core component of RISC complexes. While a considerable amount of research has focused on RNA interference and its associated mechanisms, the nature and mechanisms of nucleotide recognition by the PAZ domain of EIF2C2/Ago2 have not yet been characterized. Here, we demonstrate that the EIF2C2/Ago2 PAZ domain has an inherent lack of binding to adenine nucleotides, a feature that highlights the poor binding of 3′-adenylated RNAs with the PAZ domain as well as the selective high trimming of the 3′-ends of miRNA containing adenine nucleotides. We further show that the PAZ domain selectively binds all ribonucleotides (except adenosine), whereas it poorly recognizes deoxyribonucleotides. In this context, the modification of dTMP to its ribonucleotide analogue gave a drastic improvement of binding enthalpy and, hence, binding affinity. Additionally, higher in vivo gene silencing efficacy was correlated with the stronger PAZ domain binders. These findings provide new insights into the nature of the interactions of the EIF2C2/Ago2 PAZ domain.
Collapse
Affiliation(s)
- Mahmoud Kandeel
- Department of Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine and Animal Resources, King Faisal University, Alhofuf, Alahsa, Saudi Arabia
- Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelshikh University, Kafrelshikh, Egypt
| | - Abdullah Al-Taher
- Department of Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine and Animal Resources, King Faisal University, Alhofuf, Alahsa, Saudi Arabia
| | - Remi Nakashima
- United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan
| | - Tomoya Sakaguchi
- Department of Biomolecular Science, Faculty of Engineering, Gifu University, Gifu, Japan
| | - Ali Kandeel
- Department of Biology, Faculty of Sciences and Arts, Alkamil Branch, King Abdul Aziz University, Alkamil, Saudi Arabia
- Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt
| | - Yuki Nagaya
- Department of Biomolecular Science, Faculty of Engineering, Gifu University, Gifu, Japan
| | - Yoshiaki Kitamura
- United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan
| | - Yukio Kitade
- United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan
- Department of Biomolecular Science, Faculty of Engineering, Gifu University, Gifu, Japan
- * E-mail:
| |
Collapse
|
4
|
Wang WS, Yang XS, Xia M, Jiang HY, Hou JQ. Silencing of twist expression by RNA interference suppresses epithelial-mesenchymal transition, invasion, and metastasis of ovarian cancer. Asian Pac J Cancer Prev 2013; 13:4435-9. [PMID: 23167357 DOI: 10.7314/apjcp.2012.13.9.4435] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
PURPOSE This study aimed to explore the role of the Twist gene in the epithelial-mesenchymal transition of ovarian cancer. METHODS An RNA interference plasmid expressing a small interfering RNA (siRNA)-targeting Twist (Twist siRNA vector) was designed, constructed, and transfected into the human ovarian cancer cell line A2780. Transfection efficiency was assessed under a fluorescence microscope. Changes in the expression of Twist mRNA in A2780 after transfection with the pGenesil Twist shRNA plasmid were analyzed through RT-PCR. MTT assays and adhesion experiments were applied to determine changes in proliferation and adhesion ability of A2870 after transfection with the Twist shRNA plasmid. Changes in the expression of the E-cadherin and N-cadherin proteins in A2780 after transfection with the Twist shRNA plasmid were analyzed using Western blotting. RESULT The restructuring plasmid pGenesil-Twist shRNA was constructed successfully. After 48 h of culture, 80% of the cells expressed high-intensity GFP fluorescence and stability. The expression of Twist decreased significantly after the transfection of the Twist shRNA plasmid (P<0.05). Proliferation of the transfected Twist shRNA cells showed no difference with that of the A2780-nontransfection or A2780-si-control groups (P>0.05) but the adhesion ability of A2780 decreased dramatically (P<0.05). Expression of the E-cadherin protein increased, whereas that of the N-cadherin protein decreased compared with that in the A2780-nontransfection or A2780- si-control groups (P<0.05). CONCLUSION Twist is essential for epithelial-mesenchymal transition, invasion, and metastasis of ovarian cancer.
Collapse
Affiliation(s)
- Wen-Shuang Wang
- Department of Gynecology, Yantai Yuhuangding Hospital, Yantai, China
| | | | | | | | | |
Collapse
|
5
|
Kim DD, Eng C. The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opin Investig Drugs 2012; 21:1775-88. [PMID: 22978346 DOI: 10.1517/13543784.2012.721353] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
INTRODUCTION Recently, deregulation of protein synthesis has begun to gain attention as a major player in cancer development and progression. Specifically, deregulation of the process of translation initiation appears to play a key role in oncogenesis. The PI3K/Akt/mTOR pathway is vital for cellular metabolism, growth and proliferation and thus an attractive therapeutic target in oncology. Accordingly, several mTOR inhibitors are currently being tested in many cancers including colorectal cancer (CRC). AREAS COVERED In this review, the key components of the PI3K/Akt/mTOR pathways, their molecular alterations and the inhibitors targeting the mTOR pathway in CRC are described. Complex interactions with other pathways such as the MAPK pathway are analyzed, as are possible drug combinations that target this pathway. In addition, novel strategies for use of mTOR pathway inhibitors in CRC treatment are introduced. EXPERT OPINION Clinical trials of mTOR inhibitors have been investigated in CRC. mTOR inhibitors may represent an attractive antitumor target in combination with strategies to target other pathways that may overcome resistance. Further research is needed to identify critical molecular effector mechanisms, molecular markers that predict responsiveness and potential toxicities.
Collapse
Affiliation(s)
- Dae-Dong Kim
- The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, 1515 Holcombe, Unit 426, Houston, TX 77030, USA
| | | |
Collapse
|
6
|
Towne DL, Nicholl EE, Comess KM, Galasinski SC, Hajduk PJ, Abraham VC. Development of a High-Content Screening Assay Panel to Accelerate Mechanism of Action Studies for Oncology Research. ACTA ACUST UNITED AC 2012; 17:1005-17. [DOI: 10.1177/1087057112450050] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Efficient elucidation of the biological mechanism of action of novel compounds remains a major bottleneck in the drug discovery process. To address this need in the area of oncology, we report the development of a multiparametric high-content screening assay panel at the level of single cells to dramatically accelerate understanding the mechanism of action of cell growth–inhibiting compounds on a large scale. Our approach is based on measuring 10 established end points associated with mitochondrial apoptosis, cell cycle disruption, DNA damage, and cellular morphological changes in the same experiment, across three multiparametric assays. The data from all of the measurements taken together are expected to help increase our current understanding of target protein functions, constrain the list of possible targets for compounds identified using phenotypic screens, and identify off-target effects. We have also developed novel data visualization and phenotypic classification approaches for detailed interpretation of individual compound effects and navigation of large collections of multiparametric cellular responses. We expect this general approach to be valuable for drug discovery across multiple therapeutic areas.
Collapse
Affiliation(s)
- Danli L. Towne
- Abbott Laboratories, Global Pharmaceutical Research & Development, Lead Discovery Technologies, Abbott Park, IL USA
| | - Emily E. Nicholl
- Abbott Laboratories, Global Pharmaceutical Research & Development, Lead Discovery Technologies, Abbott Park, IL USA
| | - Kenneth M. Comess
- Abbott Laboratories, Global Pharmaceutical Research & Development, Lead Discovery Technologies, Abbott Park, IL USA
| | - Scott C. Galasinski
- Abbott Laboratories, Global Pharmaceutical Research & Development, Lead Discovery Technologies, Abbott Park, IL USA
| | - Philip J. Hajduk
- Abbott Laboratories, Global Pharmaceutical Research & Development, Lead Discovery Technologies, Abbott Park, IL USA
| | - Vivek C. Abraham
- Abbott Laboratories, Global Pharmaceutical Research & Development, Lead Discovery Technologies, Abbott Park, IL USA
| |
Collapse
|
7
|
Wang SL, Yao HH, Qin ZH. Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther 2009; 9:1357-68. [DOI: 10.1517/14712590903236843] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
8
|
Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, Xu MH, Chen GQ, Han ZG, Fang JY. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol 2009; 16:2617-28. [PMID: 19517193 DOI: 10.1245/s10434-009-0555-9] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2009] [Revised: 04/07/2009] [Accepted: 05/05/2009] [Indexed: 02/06/2023]
Abstract
BACKGROUND mTOR signaling has been suggested to be an important factor involved in tumorigenesis, but its role in human colorectal cancer (CRC) has not been completely elucidated. Herein, the purpose of this study was to analyze the distribution pattern of mTOR signaling components in CRC and adenoma and to determine whether targeted inhibition of mTOR could be a potential therapeutic strategy for CRC. METHODS Immunohistochemical analysis was performed on human CRC and adenoma for mTOR signaling components, including mTOR, p70s6 K, and 4EBP1. HCT116 and SW480 human CRC cell lines were treated with siRNA directed against mTOR, and cell viability, cell cycle, and apoptosis were assessed. HCT116 and SW480 cells were injected into athymic nude mice to establish a CRC xenograft model. Mice were randomly transfected with either nontargeting control or mTOR siRNA, and tumor volume, mTOR signaling activity, and apoptosis were evaluated. RESULTS mTOR signaling components, including mTOR, p70s6 K, and 4EBP1, were highly activated in glandular elements of CRC and colorectal adenomas with high-grade intraepithelial neoplasia (HIN), with a correlation between staining intensity and depth of infiltration in CRC. Inhibition of mTOR expression using a specific mTOR siRNA resulted in considerably decreased in vitro and in vivo cell growth. CONCLUSIONS mTOR signaling is associated with the clinical pathological parameters of human CRC. siRNA-mediated gene silencing of mTOR may be a novel therapeutic strategy for CRC.
Collapse
Affiliation(s)
- Yan-Jie Zhang
- Shanghai Institute of Digestive Disease, Shanghai Jiaotong University School of Medicine Renji Hospital, Shanghai, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Detzer A, Overhoff M, Wünsche W, Rompf M, Turner JJ, Ivanova GD, Gait MJ, Sczakiel G. Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide. RNA (NEW YORK, N.Y.) 2009; 15:627-636. [PMID: 19228587 PMCID: PMC2661840 DOI: 10.1261/rna.1305209] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2008] [Accepted: 01/14/2009] [Indexed: 05/27/2023]
Abstract
In the last decade short interfering RNA (siRNA) became an important means for functional genomics and the development of gene-specific drugs. However, major technical hurdles in the application of siRNA include its cellular delivery followed by its intracellular trafficking and its release in order to enter the RNA interference (RNAi) machinery. The novel phosphorothioate-stimulated cellular uptake of siRNA contrasts other known delivery systems because it involves a caveosomal pathway in which large amounts of siRNA are delivered to the perinuclear environment, leading to measurable though moderate target suppression. Limited efficacy seems to be related to intracellular trapping of siRNA. To study the role of intracellular trafficking of siRNA for biological effectiveness we studied whether a signal peptide for trans-membrane transport of bacterial protein toxins, which is covalently attached to siRNA, can promote its release from the perinuclear space into the cytoplasm and thereby enhance its biological effectiveness. We show that attachment of the peptide TQIENLKEKG to lamin A/C-directed siRNA improves target inhibition after its PS-stimulated delivery. This is related to increased efflux of the siRNA-peptide conjugate from the ER-specific perinuclear sites. In summary, this study strongly suggests that intracellular release of siRNA leads to increased biological effectiveness. Thus covalent peptide-siRNA conjugates are proposed as new tools to study the relationship between intracellular transport and efficacy of siRNA.
Collapse
Affiliation(s)
- Anke Detzer
- Institut für Molekulare Medizin, Universität zu Lübeck and Schleswig-Holstein, Germany
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Exceptional advances in molecular biology and genetic research have expedited cancer drug development tremendously. The declared paradigm is the development of 'personalized and tailored drugs' that precisely target the specific molecular defects of a cancer patient. It is therefore appropriate to revisit the intellectual foundations of the development of such agents, as many have shown great clinical success. One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel Prize for Physiology or Medicine. His postulate of creating 'magic bullets' for use in the fight against human diseases inspired generations of scientists to devise powerful molecular cancer therapeutics.
Collapse
Affiliation(s)
- Klaus Strebhardt
- Klaus Strebhardt is at the Department of Obstetrics and Gynaecology, School of Medicine, J.W. Goethe-University, Theodour-Stern-Kai 7, 60590 Frankfurt, Germany.
| | | |
Collapse
|
11
|
Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008; 12:637-45. [PMID: 18410245 DOI: 10.1517/14728222.12.5.637] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Small interfering RNA (siRNA) has become a powerful tool in knocking down or silencing gene expression in most cells. siRNA-based therapy has shown great promise for many diseases such as cancer. Major targets for siRNA therapy include oncogenes and genes that are involved in angiogenesis, metastasis, survival, antiapoptosis and resistance to chemotherapy. OBJECTIVES This review briefly summarizes current advances in siRNA therapy and clinical applications in cancers, especially in pancreatic cancer. METHODS This review article covers several aspects of siRNA therapy in cancer, which include the types of siRNA, the delivery systems for siRNA, and the major targets for siRNA therapy. Specific attention is given to siRNA in pancreatic cancer, which is our main research focus. RESULTS/CONCLUSION siRNA can be introduced into the cells by using either chemically synthesized siRNA oligonucleotides (oligos), or vector-based siRNA (shRNA), which allows long lasting and more stable gene silencing. Nanoparticles and liposomes are commonly used carriers, delivering the siRNA with better transfection efficiency and protecting it from degradation. In combination with standard chemotherapy, siRNA therapy can also reduce the chemoresistance of certain cancers, demonstrating the potential of siRNA therapy for treating many malignant diseases. This review will provide valuable information for clinicians and researchers who want to recognize the newest endeavors within this field and identify possible lines of investigation in cancer.
Collapse
Affiliation(s)
- Chuan Huang
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | |
Collapse
|